In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...

Jasper Therapeutics (JSPR – Research Report) received a Buy rating and a $38.00 price target from UBS analyst Trung Huynh today. The company’s ...

Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We believe STAR-0310 will be the best-in-class therapy due to efficacy, safety and tolerability, and treatment burden, and could ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...

NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500 ...

ERLANGEN, GERMANY AND VILNIUS, LITHUANIA / ACCESS Newswire / February 4, 2025 / Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway ...

Citizens Jmp upgraded shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) to a strong-buy rating in a report published on Friday,Zacks.com reports. Other equities analysts have also recently ...

JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

Sarepta Therapeutics' Elevidys for DMD shows growing ... date - a Phase 3 study failed to outperform placebo on the North Star Ambulatory Assessment ("NSAA") - while Regenxbio appears to be ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...